MannKind reports positive Phase 1b INFLO-1 results for inhaled nintedanib in IPF - MNKD News | RalliesMannKind reports positive Phase 1b INFLO-1 results for inhaled nintedanib in IPF
M
MNKD• Phase 1b INFLO-1 results
- MannKind reported positive topline Phase 1b INFLO-1 results for nintedanib dry powder inhalation in idiopathic pulmonary fibrosis.
- The trial met its primary goal, showing the inhaled therapy was generally safe and well tolerated, with no serious safety issues.
- Most patients reported no cough; reported cough was mostly mild and did not drive treatment stoppages.
- Additional data will be presented at a future conference.
- Global Phase 2 INFLO-2 is actively enrolling, positioning the program for a larger test of safety and potential efficacy.
•
